Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI

BACKGROUND AND OBJECTIVES: Trastuzumab is an important targeted drug for HER2-positive gastric cancer. The treatment efficacy of a more cost-effective and accessible trastuzumab biosimilar, HLX02, was not well investigated, especially when combined with antiangiogenic treatment. In addition, the tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jianye, Dai, Wei, Li, Zhipeng, Liang, Xiangjing, Xiao, Mingjia, Xie, Chuanmiao, Li, Xinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528101/
https://www.ncbi.nlm.nih.gov/pubmed/36192709
http://dx.doi.org/10.1186/s12885-022-10136-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528101/
https://www.ncbi.nlm.nih.gov/pubmed/36192709
http://dx.doi.org/10.1186/s12885-022-10136-y

Ejemplares similares